A NEW BIOSENSOR TECHNOLOGY

LUCENTIX develops a new biosensor technology that allows patients to measure precise concentrations of analytes in a single drop of blood or saliva using a low-cost handheld device giving laboratory-quality results. Measurements that today require sample shipping, skilled personnel, tedious sample preparation and a fully equipped laboratory, can be done by patients themselves within minutes.

Read More

The LUCENTIX biosensors are based on the invention of a new type of biochemical sensing molecule. A light-producing enzyme (luciferase) is engineered to change the color of the emitted light in response to changes in analyte concentration. In absence of the analyte the molecular system emits red light, while at high analyte concentration the light is blue. More information on the scientific background can be found in a publication in the journal Nature Chemical Biology.

The technology allows quantitative measurements. The color of the emitted light changes gradually from red to blue and the exact analyte concentration can be obtained from the ratio between red and blue light.

Current prototypes: The patients pricks his finger and places a drop of blood in the single-use test strip cartridge that is inserted in the LUCENTIX device. The result of the test is available in less than 5 minutes and no sample preparation is required. The result is then transmitted and displayed on the patient's smartphone.

The technology and our current prototype are featured in this video from EPFL News.

LUCENTIX has validated its technology in a number of validation studies, among others in collaboration with the University Hospital of Lausanne (CHUV). These studies demonstrated that Lucentix' technology can be used for precise quantitative measurements in patient samples and very good agreement with gold standard laboratory-based methods were found.

The platform technology can be adapted to a large number of different analytes. Biosensors for more than 10 different analytes (small molecules and proteins) have already been developed. A selection of analytes can be found in this figure; they include some of the therapeutic drugs most commonly monitored in patients.

NEWS

New publication in Angewandte Chemie

Using antibodies as receptor proteins expands the application range of Lucentix' biosensors.

In collaboration with the lab of Prof. Kai Johnsson at EPFL, we have published a paper with the title Bioluminescent Antibodies for Point-of-Care Diagnostics (Angewandte Chemie Int. Ed. 2017, 56, 7112-7116). The publication has been covered in international news, among others in the journal Neue Zürcher Zeitung.

Read an article on EPFL News here.

Read the publication in Angewandte Chemie.

Lucentix' technology featured on EPFL News

EPFL News has covered our May 2017 publication in Angewandte Chemie Int. Ed. in this video.

The research leading to this publication was carried out in collaboration with the lab of Prof. Kai Johnsson at EPFL. The video features an explanation on the technology and a demonstration of our current prototype.

New review in Methods in Enzymology

Lucentix' biosensor technology has been reviewed in the 2017 special issue Enzymes as Sensors.

This review in Methods in Enzymology features an in-depth review on the scientific basis and design principles of our biosensors for small molecules and proteins.

Read the publication in Methods in Enzymology.

New publication in Nature Communications

New molecular mechanism developed by our team expands the reach of the Lucentix biosensor technology.

Our team has published an article in the July 2015 issue of Nature Communications describing a new biosensor mechanism that expands the sensing principle to different targets, including large proteins. The publication has received widespread media attention including a feature in the The Times.

Read an article on the EPFL website here.

Read the publication in Nature Communications.

Lucentix' technology in the Washington Post

Lucentix' technology has been featured in the Washington Post.

The Washington Post has reported on our technology in their July 22 issue.


Read the article here.



Lucentix wins CHF 100'000 in the Venture Kick final

Lucentix received CHF 130 000, the maximum funding granted by Venture Kick.

Venture Kick announced last week that the EPFL spin-off Lucentix is one of the winners of the final stage of Venture Kick and will receive CHF 100'000 to support their venture. The startup has already won CHF 30'000 in the first two stages of the competition.

Read the full story here.

ABOUT US

LUCENTIX is a young start-up at the École Polytechnique Fédérale de Lausanne (EPFL). The technology underlying the biosensors was developed by Rudolf Griss and Alberto Schena in the course of their PhD studies with Prof. Kai Johnsson.

RUDOLF GRISS

ALBERTO SCHENA

CONTACT US

If you would like to learn more or are looking for partnerships or investment opportunities, please contact us using the form below.

Lucentix SA
EPFL Innovation Park, Bâtiment C
CH-1015 Lausanne
Switzerland

SUPPORTED BY